Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)

NCT03487549 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.

NCT NCT03487549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03487549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
Lead sponsor
Verrica Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2018
Completion date
July 15, 2019
Enrollment
56 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

common wart, dna virus infections, papillomavirus infections, skin diseases, skin diseases, infectious, skin diseases, viral, tumor virus infections, verruca, verruca vulgaris, virus diseases, warts, warts hand